IDEAYA Biosciences names IDE101 development candidate for CDKN2A-deficient solid tumors
IDYA•IDEAYA Biosciences named IDE101 a development candidate for CDKN2A-deficient solid tumors and plans to file an investigational new drug application in the first half of 2027. Preclinical studies showed activity alone and in combinations with RAS or PRMT5 inhibitors.
1. Development candidate named
IDEAYA Biosciences nominated IDE101 as a development candidate targeting CDKN2A-deficient solid tumors, with an investigational new drug filing planned for the first half of 2027. Preclinical studies showed activity alone and with RAS or PRMT5 inhibitors, including IDE892; the company plans to present results at its London R&D Day.
2. Prevalence of deficiency
CDKN2A deficiency occurs in approximately 10% to 15% of solid tumors, including about 70% of pancreatic ductal adenocarcinomas.
